Armata Pharmaceuticals, Inc. (ARMP) Stock Price & Analysis
Armata Pharmaceuticals, Inc. (ARMP) rose 1.47% to USD 7.58 as of June 13, 2026 at 13:06 UTC, according to Nexqual real-time market data.
ARMP last closed at USD 7.47; the session ranged USD 7.06–7.99 on volume of 75,836 shares. Market capitalization is $278.27M, with a 52-week range of USD 1.74–16.34 (ASE). Source: Nexqual, June 13, 2026 at 13:06 UTC.
Key Statistics (as of June 13, 2026 at 13:06 UTC)
| Price | USD 7.58 |
|---|---|
| Change | ▲ 1.47% (up) |
| Previous Close | USD 7.47 |
| Open | USD 7.33 |
| Day Range | USD 7.06 – 7.99 |
| 52-Week Range | USD 1.74 – 16.34 |
| Volume | 75,836 shares |
| Market Cap | $278.27M |
| Exchange | ASE |
Technical Analysis (ARMP)
Nexqual's technical model rates ARMP "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 13, 2026 at 13:06 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.79 (neutral) |
| vs SMA50 | Below (USD 9.64) |
| MACD | -0.5 (negative) |
Analyst Ratings (ARMP)
Wall Street analysts rate ARMP "None" based on 2 analysts, with a mean price target of USD 17.5 (range USD 15–20), per Nexqual as of June 13, 2026 at 13:06 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 17.5 |
| High Target | USD 20 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ARMP)
| Next Earnings Date | 2026-08-11 |
|---|---|
| Revenue Estimate | $420,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.16 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.36 vs est -0.19 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.42 ▲ beat |
| 2025-06-30 | USD -0.29 vs est -0.39 ▲ beat |
Source: Nexqual, June 13, 2026 at 13:06 UTC.
Financials & Fundamentals (ARMP)
| Total Revenue | $5.20M |
|---|---|
| Revenue Growth (YoY) | +60.70% |
| Gross Margin | -202.13% |
| Operating Margin | -1113.44% |
| Profit Margin | +0.00% |
| Current Ratio | 0.64 |
| Total Cash | $4.75M |
| Total Debt | $373.67M |
| Free Cash Flow | $-26.14M |
Source: Nexqual, June 13, 2026 at 13:06 UTC.
Financial Health Score (ARMP)
Nexqual rates Armata Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 13, 2026 at 13:06 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $5M cash vs $374M debt |
| Cash Flow | Weak — FCF negative: -$26M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ARMP)
| Insider Ownership | +68.53% |
|---|---|
| Institutional Ownership | +10.46% |
| Shares Outstanding | 36.71M |
| Float | 11.32M |
| Short % of Float | +1.94% |
Source: Nexqual, June 13, 2026 at 13:06 UTC.
Leadership (ARMP)
Armata Pharmaceuticals, Inc. is led by Deborah L. Birx (age 68), CEO & Director, per Nexqual as of June 13, 2026 at 13:06 UTC.
| CEO & Director | Deborah L. Birx (age 68) |
|---|---|
| Vice President of Operations | Peter Hubbard |
Major Backers & Investors (ARMP)
Notable institutional backers of Armata Pharmaceuticals, Inc. include Madison Asset Management, LLC, Millennium Management, 683 Capital Management LLC, according to Nexqual as of June 13, 2026 at 13:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Madison Asset Management, LLC | 5.74% |
| Millennium Management | 0.7% |
| 683 Capital Management LLC | 0.37% |
| Edgewood Management Llc | 0.27% |
| Dauntless Investment Group, LLC | 0.25% |
| Fidelity | 0.24% |
| SEI Investments Co | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.17% |
| Geode Capital | 0.31% |
| BlackRock | 0.26% |
Source: Nexqual, June 13, 2026 at 13:06 UTC.
From Armata Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
- It develops its products using its proprietary bacteriophage-based technology.
- The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa .
- Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHGE | BiomX Inc. | USD 0.54 | ▼ 16.22% |
| TRVI | Trevi Therapeutics, Inc. | USD 14.21 | ▲ 6.04% |
| BCDA | BioCardia, Inc. | USD 0.88 | ▲ 8.64% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3.25 | ▲ 5.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 13, 2026 at 13:06 UTC. This page is informational and not investment advice.